Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 11, 2004

View Archived Issues

Antibody targeting melanoma glycoprotein-proteoglycan complex shows anticancer efficacy in vivo

Preliminary phase II data on the antitumor efficacy of TG-4010 in NSCLC

Glycotope-specific antibody shows cytotoxic activity against gastrointestinal tumor in vivo

Anti-VEGFR antibody reduces lymphangiogenesis in vivo

A selective LXR agonist shows promise as an antiatherosclerotic agent

Novel NMDA GlyB-site antagonists discovered at Gruenenthal

Bayer claims new proteasome inhibitors for asthma and cancer

Novel tachykinin NK2/NK3 ligands discovered at Merck

New 5-HT1A ligands/5-HT reuptake inhibitors covered by Merck KGaA patent

Novartis scientists prepare and test new protein kinase C inhibitors

New CDK inhibitors in early development at Pfizer

New inhibitors of ERK2, GSK-3, PKA and CDK2 presented by Vertex

U.K. manufacturing for Fluvirin fails to comply with GMP regulations

rHuEPO active in wound healing

VEGF-toxin fusion protein inhibits tumor growth in vivo

Anti-PDGF receptor alpha antibody shows promising results in rodent glioblastoma model

Cytotoxic agent by Tapestry shows higher potency than paclitaxel in vitro

MDX-060 receives orphan drug status for Hodgkin's disease

MRL-123 decreases bone resorption and increases BMD in osteoporotic women

MC-45308 demonstrates simultaneous antiplatelet and anticoagulant effects

A product derived from bovine colostrum reduces the effects of HIV-associated diarrhea

Photrex chosen as new brand name for SnET2

Sustained reduction of testosterone levels achieved with Eligard 45 mg in prostate cancer patients

Good safety profile reported for HGS-ETR2 in advanced cancer patients

Santhera grants Genzyme license for discovery of therapies for muscular diseases

Six-month priority review for Pegasys sBLA

Expansion of Biolex and Centocor collaboration

Target enrollment reached in phase II study of methylnaltrexone for POI

New phase I study of aminocandin for systemic invasive fungal infections

MG-98 enters phase II study in metastatic renal cell cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Hippocratic loath? ‘Harm’ threat from ACIP’s proposed HBV shift
BioWorld
Individual liberty and choice vs. wider public health became one predictable hinge upon which swung the often-acerbic debates at the CDC’s Advisory Committee for...
Høeg appointment as acting CDER director tied to vaccine strategy?
BioWorld
After a more than 13-year period of stability with Janet Woodcock as the head of CDER, with Patrizia Cavazzoni taking charge during the next four years of former...
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...